Advanced Implantable Cardioverter-Defibrillator

The device, called the Marquis DR, has been cleared by the US Food and Drug Administration (FDA) and has received the CE Mark.

The device also features a Cardiac Compass to monitor cardiac disease progression, faster telemetry, and a new leadless electrocardiogram (ECG) function. The Marquis DR's improved longevity is due to a modified battery design that resulted in longer battery life and the need for less-frequent replacement. The device has a charge time of only 7.5 seconds after an eight-year service life, which makes it comparable or better than existing ICDs at implant, says the developer, Medtronic, Inc. (Minneapolis, MN, USA). The Marquis DR is remote-ready and compatible with Medtronic's CareLink Network, which allows patients to remotely download information to a secure server.

"With Marquis DR, we continue to extend and enhance our industry-leading ICD product line with truly significant improvements for our physican customers and their patients,” said Steve Mahle, president of cardiac rhythm management at Medtronic.




Related Links:
Medtronic